Claims for Patent: 10,738,092

Summary for Patent: 10,738,092

Title:	Muteins of a1m lipocalin and method of production therefor
Abstract:	The present disclosure relates to a collection of novel muteins derived from human α1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a α1m mutein capable of specifically binding to one or more targets other than a target to which wild-type α1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type α1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of α1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.
Inventor(s):	Arne Skerra, Winfried Meining, Evelyn Eggenstein
Assignee:	Technische Universitaet Muenchen
Application Number:	US15/680,970

Details for Patent 10,738,092

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	10,738,092	2037-08-18

International Patent Family for US Patent 10,738,092

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2013113851
United States of America	9758554
United States of America	2018066028